Rongsheng Biology
逻晟生物
elsewhere's corpus offers only a thin profile of Rongsheng Biology (逻晟生物). It appears in FreeS Fund's (峰瑞资本) own write-ups as one of the innovative drug and new-therapy companies the fund has backed — listed alongside names like Novita, 炎明生物, and 科因生物 in a 2021 piece, and alongside JeniVision and 渤因生物 in 2020 summit recaps . Beyond the fact of FreeS Fund's investment, the material gives no details on its founding, team, pipeline, or therapeutic focus — elsewhere's corpus does not substantively cover this company.
AI-generated — may contain errors, please verify.
Coverage
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Li Feng: One Chart to Decode Biotech Innovation Opportunities | Your Complete Guide to the FreeS Fund 2020 Biomedical Summit
Three Livestreams and One Offline Symposium, Decoding the Era of Biomedical Innovation
FreeS Fund Healthcare Open Day Is Here: Entering the Grand Era of Biomedical Innovation
Looking for China's Genentech, Moderna, Alnylam, Spark, Nimbus Therapeutics
